News | January 08, 2026
Lilly to buy Ventyx Biosciences for $1.2 billion
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
The approval is supported by data from three pivotal clinical trials
The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
It performs white blood cell differential counts and quantifies red blood cell and platelet morphology,
Applications include detailed scientific rationale and supporting clinical evidence
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Subscribe To Our Newsletter & Stay Updated
